ArticleNature biotechnology2026
Internal cap-initiated translation for efficient protein production from circular mRNA.
Erratum issuedAbstract read
In one paragraph
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Bioengineering strategies for improving the immunogenicity of mRNA vaccines.Signal transduction and targeted therapy · 2026Review
- Circular Photocaged mRNA for Light-induced Late-stage Activation of Translation.Angewandte Chemie (International ed. in English) · 2026Article
- Research Progress, Application, and Industrialization Prospects of Circular RNA Vaccines in Viral Diseases.Vaccines · 2026Review
- Programmable in vivo mRNA circularization for enhanced gene expression in bacteria.Nucleic acids research · 2026Article
- IVT-free, chemically synthesized protein-encoding RNA oligonucleotides for rapid production of personalized cancer vaccines.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- RiboScreenBiomedicines · 2026Review
- Programmable Nucleic Acid Sensing in Human Cells Using Circularizable ssDNA.Nature communications · 2026Article
- Circular RNA-mediated regulation of key signaling pathways in cardiovascular diseases: a review.Journal of advanced research · 2026Review
- Enhancement of Therapeutic mRNA Translation in Cellular Stress Conditions.International journal of molecular sciences · 2026Review
- "More" Artificial mRNAs: Beyond the Art of Nature.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- The mRNA-Based Innovative Strategy: Progress and Challenges.Nano-micro letters · 2026Review
- Emerging functions of m6A-modified circRNAs and their targeting strategies in lung cancer.Frontiers in cell and developmental biology · 2026Review
- Review
- RNA chemistry and therapeutics.Nature reviews. Drug discovery · 2025Review
- Localized 2'-OH Acylation at Poly(A) Extends RNA Translation.Journal of the American Chemical Society · 2025Article
- Exploring the Potential and Advancements of Circular RNA Therapeutics.Exploration (Beijing, China) · 2025Review
- Chemical circularization of in vitro transcribed RNA for exploring circular mRNA design.Nature communications · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
21 authors.
Kosuke Fukuchi *Department of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.
Yuko Nakashima *Department of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.ORCID http://orcid.org/0000-0002-5597-0309
Naoko Abe *Department of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan. naokoabe@chem.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0001-6062-3515
Seigo KimuraIntegrated Research Consortium on Chemical Sciences (IRCCS), Nagoya University, Nagoya, Japan.ORCID http://orcid.org/0000-0001-6382-6908
Fumitaka HashiyaResearch Center for Materials Science, Nagoya University, Nagoya, Japan.
Yuichi ShichinoRNA Systems Biochemistry Laboratory, RIKEN Cluster for Pioneering Research, Saitama, Japan.ORCID http://orcid.org/0000-0002-0093-1185
Yiwei LiuDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.ORCID http://orcid.org/0000-0002-8072-0715
Ryoko OgisuDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.
Satomi SugiyamaDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.
Daisuke KawaguchiDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.
Masahito InagakiDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.ORCID http://orcid.org/0000-0001-9556-4586
Zheyu MengDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.
Shiryu KajiharaDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.
Mizuki TadaDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.
Satoshi UchidaMedical Research Institute, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Ting-Ting LiDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.
Ramkrishna MaityDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.
Tairin KawasakiDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.
Yasuaki KimuraDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan.ORCID http://orcid.org/0000-0002-3609-602X
Shintaro IwasakiRNA Systems Biochemistry Laboratory, RIKEN Cluster for Pioneering Research, Saitama, Japan.ORCID http://orcid.org/0000-0001-7724-3754
Hiroshi AbeDepartment of Chemistry, Graduate School of Science, Nagoya University, Nagoya, Japan. abe.hiroshi.p4@f.mail.nagoya-u.ac.jp.ORCID http://orcid.org/0000-0003-0048-3789
Funding
Japan Agency for Medical Research and Development (AMED) JP20gm1410001Japan Agency for Medical Research and Development (AMED) JP21gm0010008Japan Agency for Medical Research and Development (AMED) JP22fk0310506Japan Agency for Medical Research and Development (AMED) JP23ab0123456Japan Agency for Medical Research and Development (AMED) JP23bm1223009Japan Agency for Medical Research and Development (AMED) JP23fk0310506Japan Agency for Medical Research and Development (AMED) JP23gm6910005Japan Agency for Medical Research and Development (AMED) JP243fa827006Japan Agency for Medical Research and Development (AMED) JP243fa827032Japan Society for the Promotion of Science London (JSPS London) JP23H02415MEXT | Japan Science and Technology Agency (JST) JPMJCR23N1MEXT | Japan Society for the Promotion of Science (JSPS) JP21395993MEXT | Japan Society for the Promotion of Science (JSPS) JP23H04268MEXT | Japan Society for the Promotion of Science (JSPS) JP23K05648MEXT | Japan Society for the Promotion of Science (JSPS) JP2522K14796MEXT | JST | Core Research for Evolutional Science and Technology (CREST) JPMJCR18S1
Abstract
Circular mRNA faces challenges in enhancing its translation potential as an RNA therapeutic. Here we introduce two molecular designs that bolster circular mRNA translation through an internal cap-initiated mechanism. The first consists of a circular mRNA with a covalently attached N
Indexed as
Protein BiosynthesisRNA CapsRNA, CircularRNA, MessengerAnimalsHumansInternal Ribosome Entry SitesMiceInternal Ribosome Entry SitesRNA CapsRNA, CircularRNA, Messenger
Identifiers
PMID
39972222What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.